The MHRA has approved eplontersen (Wainzua) for treating adults with polyneuropathy associated with hereditary transthyretin ...

or reactive systemic amyloidosis resulting from deposits of catabolic products of the serum amyloid A protein (SAA); and ATTR due to transthyretin (TTR) accumulation. There are also amyloidoses in ...

It is caused by a mutant form of the transthyretin (TTR) protein that can damage vital organs in your body. Because it ...

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra (vutrisiran), is made by Alnylam Pharmaceuticals and is used to treat protein ...

and is used to treat transthyretin amyloid cardiomyopathy ... It uses RNA technology to stop the body from making the bad protein, while the other treatments work to stabilize the protein before ...

whereby amyloid fibrils made from misfolded transthyretin protein accumulate in the heart. In most patients, death is caused by sudden heart failure or heart-related issues. The trial revealed ...

UK MHRA approves eplontersen to treat adults with rare inherited nerve disease or polyneuropathy: United Kingdom Monday, April 7, 2025, 15:00 Hrs [IST] The Medicines and Healthcar ...

hATTR is an ultra-rare progressive condition that causes the liver to produce abnormal transthyretin protein that accumulates in the body, causing multiple symptoms including damage to the ...

Transthyretin is a specific amyloid protein that your body deposits into your heart if you have ATTR-CM. The protein usually transports vitamin A and thyroid hormones through your body.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wainzua (eplontersen) to treat adults with polyneuropathy associated with hereditary transthyretin amyloidosis (ATTRv), ...